Literature DB >> 17361438

Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA.

Sebastian Kreiter1, Thorsten Konrad, Martina Sester, Christoph Huber, Ozlem Türeci, Ugur Sahin.   

Abstract

Assessment of antigen-specific T-cell responses has been greatly facilitated by development of ELISPOT and intracellular cytokine flow cytometry (CFC) assays. The use of autologous antigen presenting cells transfected with in vitro transcribed RNA as stimulators allows in principle quantification of antigen-specific T-cells independent of the knowledge of the epitopes. We describe here a cytokine secretion assay that enables simultaneous assessment of both antigen-specific CD4+ as well as CD8+ T-cells directly from clinical samples without the need for generation of dendritic cells. To this aim, bulk PBMCs were electroporated with RNA encoding the antigen fused to trafficking signal sequences derived from a MHC class I molecule and used as stimulators. With human cytomegalovirus (HCMV) phosphoprotein 65 (pp65) as antigen we show that for measuring ex vivo T-cell responses in ELISPOT and CFC such stimulators are superior or at least equivalent to a pool of overlapping peptides representing the entire pp65 sequence as well as to untagged pp65 encoding RNA. This approach avoids the time consuming generation of dendritic cells as immune stimulators and, in particular when used in the context of the CFC, is robust, broadly applicable and fast.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361438     DOI: 10.1007/s00262-007-0302-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening.

Authors:  Alexandra G Orlandini von Niessen; Marco A Poleganov; Corina Rechner; Arianne Plaschke; Lena M Kranz; Stephanie Fesser; Mustafa Diken; Martin Löwer; Britta Vallazza; Tim Beissert; Valesca Bukur; Andreas N Kuhn; Özlem Türeci; Ugur Sahin
Journal:  Mol Ther       Date:  2018-12-18       Impact factor: 11.454

Review 2.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

3.  Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation.

Authors:  Patrick Kleemann; Eva Distler; Eva M Wagner; Simone Thomas; Sebastian Klobuch; Steffi Aue; Elke Schnürer; Hansjörg Schild; Matthias Theobald; Bodo Plachter; Stefan Tenzer; Ralf G Meyer; Wolfgang Herr
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

4.  A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity.

Authors:  Tim Beissert; Mario Perkovic; Annette Vogel; Stephanie Erbar; Kerstin C Walzer; Tina Hempel; Silke Brill; Erik Haefner; René Becker; Özlem Türeci; Ugur Sahin
Journal:  Mol Ther       Date:  2019-09-12       Impact factor: 11.454

5.  A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.

Authors:  Anna H Malczyk; Alexandra Kupke; Steffen Prüfer; Vivian A Scheuplein; Stefan Hutzler; Dorothea Kreuz; Tim Beissert; Stefanie Bauer; Stefanie Hubich-Rau; Christiane Tondera; Hosam Shams Eldin; Jörg Schmidt; Júlia Vergara-Alert; Yasemin Süzer; Janna Seifried; Kay-Martin Hanschmann; Ulrich Kalinke; Susanne Herold; Ugur Sahin; Klaus Cichutek; Zoe Waibler; Markus Eickmann; Stephan Becker; Michael D Mühlebach
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

6.  Selective activation of trophoblast-specific PLAC1 in breast cancer by CCAAT/enhancer-binding protein beta (C/EBPbeta) isoform 2.

Authors:  Michael Koslowski; Ozlem Türeci; Stefan Biesterfeld; Gerhard Seitz; Christoph Huber; Ugur Sahin
Journal:  J Biol Chem       Date:  2009-08-03       Impact factor: 5.157

7.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

Authors:  Lena M Kranz; Mustafa Diken; Heinrich Haas; Sebastian Kreiter; Carmen Loquai; Kerstin C Reuter; Martin Meng; Daniel Fritz; Fulvia Vascotto; Hossam Hefesha; Christian Grunwitz; Mathias Vormehr; Yves Hüsemann; Abderraouf Selmi; Andreas N Kuhn; Janina Buck; Evelyna Derhovanessian; Richard Rae; Sebastian Attig; Jan Diekmann; Robert A Jabulowsky; Sandra Heesch; Jessica Hassel; Peter Langguth; Stephan Grabbe; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2016-06-01       Impact factor: 49.962

8.  Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.

Authors:  Nikoletta Lendvai; Sacha Gnjatic; Erika Ritter; Michael Mangone; Wayne Austin; Karina Reyner; David Jayabalan; Ruben Niesvizky; Sundar Jagannath; Nina Bhardwaj; Selina Chen-Kiang; Lloyd J Old; Hearn Jay Cho
Journal:  Cancer Immun       Date:  2010-01-29

Review 9.  Synthetic modified messenger RNA for therapeutic applications.

Authors:  Minsong Gao; Qingyi Zhang; Xin-Hua Feng; Jianzhao Liu
Journal:  Acta Biomater       Date:  2021-06-13       Impact factor: 8.947

Review 10.  Whole Tumor Antigen Vaccines: Where Are We?

Authors:  Cheryl Lai-Lai Chiang; George Coukos; Lana E Kandalaft
Journal:  Vaccines (Basel)       Date:  2015-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.